Company profile

Pasithea Therapeutics Corp.

Pipeline4 assets

PAS-004PAS-004 / MEK 1/2 / Macrocyclic Small Molecule / Oncology / Rare Diseases
Neurofibromatosis type 1-associated plexiform neurofibromas (NF1-PN)MAPK pathway-driven advanced solid tumors
PAS-003PAS-003 / α5β1 Integrin / Monoclonal Antibody / Neurology
Amyotrophic Lateral Sclerosis (ALS)
PAS-001PAS-001 / C4A / Small Molecule / Psychiatry
Schizophrenia
PAS-002PAS-002 / Neurology
Multiple Sclerosis (MS)

Latest news6 items

May 4, 2026

Pasithea Therapeutics Announces Appointment of Kartik Krishnan, M.D., Ph.D. as Chief Medical Officer

Apr 20, 2026

Pasithea Therapeutics Announces Grant of Rare Pediatric Disease Designation (RPDD) by FDA to PAS-004 for Treatment of Neurofibromatosis Type 1 (NF1)

Apr 1, 2026

Pasithea Therapeutics Announces Grant of Fast Track Designation by FDA to PAS-004 for Treatment of Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN) Causing Significant Morbidity

Feb 17, 2026

Pasithea Therapeutics to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference

Jan 13, 2026

Pasithea Therapeutics Provides Outlook on PAS-004 Clinical Programs and Data Release Timelines

Dec 2, 2025

Pasithea Therapeutics Announces Closing of $60 Million Public Offering of Common Stock

Pasithea Therapeutics Corp. • Endpoint Arena